...
首页> 外文期刊>Artificial cells, nanomedicine, and biotechnology. >Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer
【24h】

Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer

机译:脂质体阿霉素负载的基于PLGA-PEG-PLGA的热凝胶可用于持续局部药物递送以治疗乳腺癌

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The aim of this research is to utilize a hybrid system of liposomal doxorubicin (DOX-Lip) loaded thermogel (DOX-Lip-Gel) to realize the steady sustained delivery of doxorubicin (DOX), a small hydrophilic drug, for the treatment of breast cancer locally. Herein, liposomal doxorubicin was prepared via the traditional film dispersion method with the particle size of 75?nm and drug entrapment efficiency of 86%. And, the triblock copolymer of poly (D, L-lactide-co-glycolide)-b-poly (ethylene glycol)-b-poly (D, L-lactide -co-glycolide) (PLGA-PEG-PLGA) was synthesized via ring-opening polymerization to prepare the thermosensitive hydrogel through dissolving the polymers in DOX-Lip solution. The liposome loaded hydrogel was in a sol state at room temperature and converted into the gel state at body temperature and would degrade gradually during the time in vivo . The drug release of DOX out of DOX-Lip-Gel could be in a steady sustained manner up to 11?days without significant burst release as compared to that of DOX-loaded hydrogel (DOX-Gel). An orthotopic breast cancer model was adopted to evaluate the in vivo antitumor efficacy. And, the results revealed DOX-Lip-Gel had better antitumor efficiency as well as lower side effects.
机译:这项研究的目的是利用载有脂质体阿霉素(DOX-Lip)的热凝胶(DOX-Lip-Gel)的混合系统来实现稳定持续递送一种小型亲水性药物阿霉素(DOX),用于治疗乳房局部癌症。此处,阿霉素脂质体是通过传统的膜分散法制备的,粒径为75?nm,药物包封率为86%。并且,合成了聚(D,L-丙交酯-乙交酯)-b-聚(乙二醇)-b-聚(D,L-丙交酯-乙交酯)(PLGA-PEG-PLGA)的三嵌段共聚物。通过开环聚合将聚合物溶解在DOX-Lip溶液中来制备热敏水凝胶。负载脂质体的水凝胶在室温下处于溶胶状态,在人体温度下转化为凝胶状态,并在体内逐渐降解。与装载DOX的水凝胶(DOX-Gel)相比,DOX从DOX-Lip-Gel中释放出来的药物可以稳定持续长达11天,而没有明显的突释。采用原位乳腺癌模型评估体内抗肿瘤功效。并且,结果表明DOX-Lip-Gel具有更好的抗肿瘤功效以及更低的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号